Search Results for: -uju5o2q.html

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the initiation of two additional clinical studies with its lead molecule, 9-ING-41, a Glycogen Synthase Kinase beta (GSK-3β) inhibitor. On April 8, the company opened its 1902 study: A Phase 1 study of 9-ING-41, a Glycogen Synthase […]

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41 Read More »

ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised an additional $6.5M in a Series B-3 financing round. This Series B-3 was led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating, and brings total funding for Actuate’s Series B

ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS Read More »

ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round. The Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners, participating. Actuate will use the proceeds of the

ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING Read More »

Secret Link